Latest Stereotaxis (STXS) Headlines 20.2% Retur
Post# of 66
20.2% Return Seen to Date on SmarTrend Stereotaxis Call (STXS)
Comtex SmarTrend(R) - Tue Mar 04, 5:21PM CST
SmarTrend identified an Uptrend for Stereotaxis (NASDAQ:STXS) on December 23rd, 2013 at $4.20. In approximately 2 months, Stereotaxis has returned 20.24% as of today's recent price of $5.05.
Nasdaq stocks posting largest percentage decreases
AP - Wed Feb 26, 12:51PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Stereotaxis Signs Distribution Agreement for Niobe(R) Technology in Japan
GlobeNewswire - Tue Feb 25, 3:06PM CST
Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has entered into a definitive agreement with Medix Japan, Inc. and Hokushin Medical Co. Ltd. to distribute its Niobe(R) Magnetic Navigation System for cardiac ablations in Japan. The agreement ensures sales and marketing coverage for Stereotaxis in an electrophysiology (EP) market performing approximately 47,000 procedures each year and expected to grow at an annual rate of 10% through 2018. Japan also represents one of the largest medical device markets globally, second to the U.S.
Stereotaxis Reports 2013 Fourth Quarter and Full Year Financial Results
GlobeNewswire - Tue Feb 25, 3:05PM CST
-Announces Distribution Partnership in Japan-
Stereotaxis Up 35.2% Since SmarTrend Uptrend Call (STXS)
Comtex SmarTrend(R) - Tue Feb 25, 10:58AM CST
SmarTrend identified an Uptrend for Stereotaxis (NASDAQ:STXS) on December 23rd, 2013 at $4.20. In approximately 2 months, Stereotaxis has returned 35.24% as of today's recent price of $5.68.
Stereotaxis to Report Fourth Quarter and Full Year 2013 Financial Results on February 25, 2014
GlobeNewswire - Wed Feb 19, 5:30AM CST
Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will release financial results for its 2013 fourth quarter and full year ended December 31, 2013 on Tuesday, February 25, 2014 after the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the Company's results and corporate developments.
Shares of STXS Up 39.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 18, 9:39AM CST
SmarTrend identified an Uptrend for Stereotaxis (NASDAQ:STXS) on December 23rd, 2013 at $4.20. In approximately 2 months, Stereotaxis has returned 39.76% as of today's recent price of $5.87.
Stereotaxis Appoints William C. Mills III to Chief Executive Officer
GlobeNewswire - Fri Feb 14, 5:30AM CST
Stereotaxis, Inc. (Nasdaq:STXS) announced today that its board of directors has appointed Chairman William C. Mills III to Chief Executive Officer, effective February 12, 2014. Mr. Mills has been serving as interim CEO since April 2013.
Shares of STXS Up 22.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 11, 9:09AM CST
SmarTrend identified an Uptrend for Stereotaxis (NASDAQ:STXS) on December 23rd, 2013 at $4.20. In approximately 2 months, Stereotaxis has returned 22.86% as of today's recent price of $5.16.
5 Stocks Ready to Break Out
at The Street - Fri Jan 17, 12:24PM CST
These stocks are poised to break out and trade higher from current levels.
4 Stocks Under $10 Moving Higher
at The Street - Wed Jan 15, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Why Stereotaxis Inc. (STXS) is Up Today
at The Street - Tue Jan 07, 11:06AM CST
Stereotaxis Inc. (STXS) rose 18% in Tuesday morning trading after the company announced the completion of an FDA trial.
Notable Buzzers: Apple Inc, Stereotaxis Inc, Tiger Oil and Energy Inc, Gilead Sciences Inc
ACCESSWIRE - Tue Jan 07, 10:00AM CST
New York, January 07, 2014 / Accesswire / - Market Buzz Report, which provides live alerts on penny stocks, issues critical stocks analysis for Apple Inc. (NASDAQ:AAPL), Stereotaxis Inc (NASDAQ:STXS), Tiger Oil and Energy, Inc. (TGRO), Gilead Sciences, Inc. (NASDAQ:GILD).
Stereotaxis Completes Clinical Trial of Vdrive(TM) With V-Loop(TM) System
GlobeNewswire - Tue Jan 07, 5:30AM CST
Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has completed the clinical trial required for FDA clearance of the Company's Vdrive(TM) Robotic Navigation System with V-Loop(TM) Circular Catheter Manipulator. Results of the 120-patient study, which was conducted at three Stereotaxis sites in the U.S. and two in Europe, will be included in a 510(k) Premarket Notification the Company intends to submit in the first quarter of 2014.
5 Stocks Poised for Breakouts
at The Street - Fri Dec 20, 1:07PM CST
These stocks look ready to break out and trade higher from current levels.